(Q80241635)
Statements
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma (English)
J P Leonard
J W Friedberg
A Younes
D Fisher
J Moore
M Czuczman
T Miller
P Stiff
A Forero-Torres
N Chieffo
B McKinney
D Finucane